Ines Nikolovski1, Maria I Carlo2, Ying-Bei Chen3, Hebert Alberto Vargas4. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St #1407, NY, 10065, New York, USA. nikolovi@mskcc.org. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St #1407, NY, 10065, New York, USA.
Abstract
BACKGOUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging. METHODS: This single-site retrospective study included patients with histologically confirmed FH-RCC or with a renal cancer and known germline FH mutation; imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI, or FDG PET/CT between October 2007 and May 2019. Clinical information, pathological data, and imaging features were analyzed and reported descriptively. RESULTS: Sixteen patients with sixteen tumors were included (median age 46 years, interquartile range 38-53 years; 31 % female). Almost all tumors were unifocal (15/16, 94 %). Most tumors had infiltrative margins (14/16, 88 %); few were circumscribed (2/16, 12 %). A large cystic tumor component (> 75 % of tumor volume) was seen in 8/16 (50 %) of tumors. Involvement of renal sinus fat was seen in 13/16 (81 %) of tumors, involvement of the hilar collecting system in 8/16 (50 %), and renal vein tumor thrombus in 6/16 (38 %). All 12 tumors (100 %) imaged with MRI had heterogenous tumor enhancement and heterogenous T2 signal. Of those patients that had diffusion-weighted imaging, 11/11 (100 %) of tumors had diffusion restriction in the solid portions of the tumor. Of the patients who had PET, 3/3 (100 %) tumors showed high metabolic activity with mean maximum standardized uptake value (SUVmax) of 16.4 (range 9.6-21.9). Patients presented with retroperitoneal nodal metastases in 69 % of cases and distant metastases in 75 %. Of those four patients without metastatic disease at presentation, three (75 %) developed metastases within 4 years of diagnosis. CONCLUSIONS: In our study, the majority of tumors (≥ 75 %) were unifocal, had an infiltrative margin, invaded the renal sinus fat, and presented with distant metastases. On MRI, most tumors had heterogenous T2 signal and diffusion restriction in their solid components. The small number of cases that had PET imaging showed high metabolic activity.
BACKGOUND: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging. METHODS: This single-site retrospective study included patients with histologically confirmed FH-RCC or with a renal cancer and known germline FH mutation; imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI, or FDG PET/CT between October 2007 and May 2019. Clinical information, pathological data, and imaging features were analyzed and reported descriptively. RESULTS: Sixteen patients with sixteen tumors were included (median age 46 years, interquartile range 38-53 years; 31 % female). Almost all tumors were unifocal (15/16, 94 %). Most tumors had infiltrative margins (14/16, 88 %); few were circumscribed (2/16, 12 %). A large cystic tumor component (> 75 % of tumor volume) was seen in 8/16 (50 %) of tumors. Involvement of renal sinus fat was seen in 13/16 (81 %) of tumors, involvement of the hilar collecting system in 8/16 (50 %), and renal vein tumor thrombus in 6/16 (38 %). All 12 tumors (100 %) imaged with MRI had heterogenous tumor enhancement and heterogenous T2 signal. Of those patients that had diffusion-weighted imaging, 11/11 (100 %) of tumors had diffusion restriction in the solid portions of the tumor. Of the patients who had PET, 3/3 (100 %) tumors showed high metabolic activity with mean maximum standardized uptake value (SUVmax) of 16.4 (range 9.6-21.9). Patients presented with retroperitoneal nodal metastases in 69 % of cases and distant metastases in 75 %. Of those four patients without metastatic disease at presentation, three (75 %) developed metastases within 4 years of diagnosis. CONCLUSIONS: In our study, the majority of tumors (≥ 75 %) were unifocal, had an infiltrative margin, invaded the renal sinus fat, and presented with distant metastases. On MRI, most tumors had heterogenous T2 signal and diffusion restriction in their solid components. The small number of cases that had PET imaging showed high metabolic activity.
Entities:
Keywords:
FH-deficient; HLRCC; Hereditary leiomyomatosis and renal cell carcinoma syndrome
Authors: H J Lehtonen; M Kiuru; S K Ylisaukko-Oja; R Salovaara; R Herva; P A Koivisto; O Vierimaa; K Aittomäki; E Pukkala; V Launonen; L A Aaltonen Journal: J Med Genet Date: 2005-09-09 Impact factor: 6.318
Authors: Chisato Ohe; Steven C Smith; Deepika Sirohi; Mukul Divatia; Mariza de Peralta-Venturina; Gladell P Paner; Abbas Agaimy; Mitual B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Maurizio Colecchia; Eva Compérat; Isabela Werneck da Cunha; Jonathan I Epstein; Anthony J Gill; Ondřej Hes; Michelle S Hirsch; Wolfram Jochum; Lakshmi P Kunju; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Gabriella Nesi; Adeboye O Osunkoya; Maria M Picken; Priya Rao; Victor E Reuter; Paulo Guilherme de Oliveira Salles; Luciana Schultz; Satish K Tickoo; Scott A Tomlins; Kiril Trpkov; Mahul B Amin Journal: Am J Surg Pathol Date: 2018-03 Impact factor: 6.394
Authors: V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen Journal: Proc Natl Acad Sci U S A Date: 2001-02-27 Impact factor: 11.205
Authors: Ying-Bei Chen; A Rose Brannon; Antoun Toubaji; Maria E Dudas; Helen H Won; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; Norma Frizzell; Martin H Voss; Paul Russo; Michael F Berger; Satish K Tickoo; Victor E Reuter Journal: Am J Surg Pathol Date: 2014-05 Impact factor: 6.394
Authors: Steven C Smith; Deepika Sirohi; Chisato Ohe; Jonathan B McHugh; Jason L Hornick; Jigna Kalariya; Sushil Karia; Katie Snape; Shirley V Hodgson; Andi K Cani; Daniel Hovelson; Daniel J Luthringer; Guido Martignoni; Ying-Bei Chen; Scott A Tomlins; Rohit Mehra; Mahul B Amin Journal: Histopathology Date: 2017-04-12 Impact factor: 5.087
Authors: Kristyna Pivovarcikova; Petr Martinek; Petr Grossmann; Kiril Trpkov; Reza Alaghehbandan; Cristina Magi-Galluzzi; Maria Pane Foix; Enric Condom Mundo; Daniel Berney; Anthony Gill; Boris Rychly; Kvetoslava Michalova; Joanna Rogala; Tomas Pitra; Tamas Micsik; Jiri Polivka; Milan Hora; Ozlem Tanas Isikci; Sarka Skalova; Jana Mareckova; Michal Michal; Ondrej Hes Journal: Ann Diagn Pathol Date: 2019-02-10 Impact factor: 2.090
Authors: Brian Shuch; Shantao Li; Harvey Risch; Ranjit S Bindra; Patrick D McGillivray; Mark Gerstein Journal: Cancer Date: 2020-05-15 Impact factor: 6.860